Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Investor Day (March 2026)
99 slides from Arcticzymes Technologies Asa's investor day presentation, Mar 6, 2026
Slide 1: Capital Markets Day 2026: Focused, Scalable & Profitable
Capital Markets Day 2026 Focused, Scalable & Profitable. Stockholm, 06.03.2026
Slide 2: Todays Framework: How We Create Long-Term Value
Todays Framework How We Create Long-Term Value Strategic Evolution 1 How ArcticZymes has transformed The building blocks of ArcticZymes’ Market & Growth Strategy long-term value 2 Where we compete and grow creation Customer Validation 3 Real impact in customer workflows Commercial Engine 4 How we co
Slide 3: Agenda
Agenda How We Create Long-Term Value 9.00 - 9.15 am Introduction | Michael Akoh - CEO 9.15 - 9.30 am Market Opportunity | Steve Dey – Director of Product Management and Marketing 9.30 - 9.50 am Growth Strategy | Steve Dey – Director of Product Management and Marketing 9.50 - 10.00 am Q&A 10.10 - 10.
Slide 4: Meet your Hosts
Meet your Hosts Todays Speakers Michael Akoh Børge Sørvoll Paul Blackburn Chief Executive Officer Chief Financial Officer Chief Commercial Officer Steve Dey Lee Davies Rafi Ahmad Director of Product Senior Director - Innovation Professor & Group leader of the Management and Marketing OXB Strategic R
Slide 5: Why We Are Here Today?
Why We Are Here Today? Company and market evolution demands new clear strategic direction Company Evolution Market Maturity New Strategic Clarity Renewed board and Increased capital discipline • Clear growth ambition leadership team and regulatory scrutiny • Defined strategy and priorities Strengthe
Slide 6: A unique, scalable and profitable enzyme platform
A unique, scalable and profitable enzyme platform Who we are 30+ Years experience Strengthening market position - more customers seeing the value of our high-performance enzymes 360+ unique customers Norwegian enzyme provider with industry Biomanufactering knowledge built over several decades 450 CO
Slide 7: Strong values and a clear strategic foundation
Strong values and a clear strategic foundation Our vision and mission Vision Mission Be the trusted partner in enzyme-driven Enable safer, more effective therapies and innovation across molecular diagnostics and diagnostics through high-performance advanced therapies enzymes 7
Slide 8: Decoding Biology
Decoding Biology Enzymes: Precision Tools at the Core of In our context, enzymes are used in: Regulated Life Science Workflows Manufacturing of advanced therapies (e.g., viral vectors and RNA therapeutics) Enzymes are precision biological proteins that control and accelerate specific chemical reacti
Slide 9: Scaling Our Platform for Durable Growth
Scaling Our Platform for Durable Growth Platform built for operating leverage High gross margin Scalable cost structure products Recurring reagent Platform expansion consumption Designed to compound over time 9
Slide 10: Establishing a Scalable Enzyme Platform
Establishing a Scalable Enzyme Platform Expanding reach, deepening customer value, broadening platform Three deliberate investments transforming ArcticZymes from product supplier to scalable platform company Commercial Product–market fit Diversification Build Out • Core enzymes across broader • Expa
Slide 11: From Pandemic Surge to Structural Growth
From Pandemic Surge to Structural Growth Deliberate platform investments now driving renewed growth Sales momentum picking up 2020–2022: 2023–2024: 2025 – onwards: (Annual revenue, MNOK) Pandemic-Driven Surge Market Return to growth. normalisation & Extraordinary demand across Revenue reset Growth l
Slide 12: Capabilities & Market Opportunities
Capabilities & Market Opportunities Stockholm, 06.03.2026
Slide 13: The ArcticZymes Advantage
The ArcticZymes Advantage Integrated capabilities enabling differentiated enzyme solutions Process Competencies Key Differentiators • Internal Innovation Arctic, sea organisms • External collaborations • 2 expression systems • 30 years experience • Salt tolerant enzymes • Expertise • Developed QC sy
Slide 14: ArcticZymes – Main Product Families
ArcticZymes – Main Product Families The Enzyme Experts Product Competencies Nucleases Enzymes which cut nucleic acid stands (DNA and RNA) Ligases Enzymes which fuse nucleic acid strands (DNA and RNA) together Polymerases Enzymes which generate nucleic acids (DNA or RNA) from a template 14
Slide 15: Target Markets for Scalable Growth
Target Markets for Scalable Growth Where to play Molecular Tools Advanced Therapies PCR Mol Dx Kits Untapped Viral Markets RNA Vector NGS Dx 15
Slide 16: PCR Diagnostics
PCR Diagnostics Stable and resilient core market Core, fast, widespread diagnostic test, used to detect specific disease targets. Applicable for both genetic and infectious diseases. Market Snapshot Core Products Customer drivers PCR Reagents Market Cost reduction ~$10B (2025) 1. Cod UNG Increased s
Slide 17: Next Generation Sequencing Diagnostics
Next Generation Sequencing Diagnostics High growth and transformational Next generation sequencing is emerging as a powerful diagnostic technique, allowing the analysis of genetic material, without the need for specific targeting. The main uses are seen in cancer diagnosis and infectious pathogen de
Slide 18: Viral Vector Market
Viral Vector Market High growth, high potential Viral vectors are engineered viruses used to deliver genetic material into patient cells, either externally or directly into the patient. Main application for viral vectors include gene therapy, cancer therapy (CAR-T) and vaccines. Market Snapshot Core
Slide 19: RNA Therapeutics Market
RNA Therapeutics Market High growth, high potential The RNA therapeutics market is a rapidly growing sector focused on developing drugs using ribonucleic acid (RNA) to treat, manage, or prevent diseases by targeting gene expression or protein production. Market Snapshot Core Products Customer driver
Slide 20: Maximising the Markets
Maximising the Markets Market diversity and growth optionality Molecular Tools Advanced Therapies PCR Diagnostic Market Viral Vector Market Mature market Fast growth, sensitive market High barrier to substitution Significant current business Significant current business Good capabilities fit NGS Dia
Slide 21: Growth Strategy
Growth Strategy Framework for Strategic Scalable Growth Stockholm, 06.03.2026
Slide 22: Diversification: Expanding Our Revenue Base
Expanding Our Revenue Base More customers. More markets. More products per workflow. The solution Increase customer base Diversification Enter new markets Increase products per market/workflow Strengthen current market positioning
Slide 23: Building a Scalable Enzyme Platform
Building a Scalable Enzyme Platform Strategic pillars accelerating growth and resilience Umbrella Strategy Customer focused market approach Transition from product-oriented enzyme supplier, to a customer centric, application lead/solutions provider Create a wider base – diversify Increase the number
Slide 24: Molecular Tools
Molecular Tools
Slide 25: Expanding Along the mgNGS Value Chain
Expanding Along the mgNGS Value Chain Targeted enzyme positions across the workflow Host cell DNA Contamination Library Prep Sample collection NA extraction (incl. amplification) Sequencing Analysis Depletion Control € € € € • Simplification • Validation • Reliability • Simplification • Speed • Regu
Slide 26: Molecular tools: Expanding our NGS Franchise
Molecular tools: Expanding our NGS Franchise Strategy Overview Build and launch a range of enzymes positioned for the NGS diagnostics workflow, while reinforcing the existing PCR business and defocusing on low value generic products. Strategic Initiatives Develop NGS portfolio, utilizing existing en
Slide 27: Viral Vector
Viral Vector 27
Slide 28: Strengthening Our Position in Viral Vector Manufacturing
Strengthening Our Position in Viral Vector Manufacturing Multiple enzymes positions across a high-growth workflow Cell Growth Clarification Vector concentration Buffer exchange Sterile filtration Quality Control € € € • Improved DNA • Wider temperatures • Wider temperatures detection • Wider salt ra
Slide 29: Viral Vectors: Scaling the Viral Vector Franchise
Viral Vectors: Scaling the Viral Vector Franchise Strategy Overview Drive and reinforce SAN sales while increasing product offering across the workflow. Investigate additional DNA vector modalities as target markets for SAN Strategic Initiatives Accelerate SANs market penetration Identify additional
Slide 30: RNA Therapeutics
RNA Therapeutics 30
Slide 31: RNA Workflow: Building Long-Term Growth in RNA Therapeutics
RNA Workflow: Building Long-Term Growth in RNA Therapeutics From repositioned assets to new product launches In Vitro Templated DNA Reaction Quenching Enzymatic Purification Sterile filtration Quality Control Transcription Digestion modification € € € € € • Efficiency gains • Efficiency gains • Effi
Slide 32: RNA Therapeutics: Building the Next Growth Platform
RNA Therapeutics: Building the Next Growth Platform Strategy Overview Build and launch a range of high value enzymes positioned for the RNA Therapeutics workflow, driving revenue and building an RNA brand through direct and OEM channels. Strategic Initiatives Launch novel RNA enzyme into the RNA The
Slide 33: Strengthening the Business Model
Strengthening the Business Model Driving Growth, Diversification and Resilience The solution Increased Growth Increase customer base Opportunities Increased Market Enter new markets Diversity Increase products per Increased Market market/workflow Resilience Strengthen current market positioning
Slide 34: Building a Scalable Commercial Engine
Building a Scalable Commercial Engine Stockholm, 06.03.2026
Slide 35: Organisational Customer Centricity
Organisational Customer Centricity Transforming the Commercial Team STRUCTURE ENABLEMENT CULTURE DISCIPLINE & IMPACT • Unified commercial • Customer-centric • Customer-first • Operational organization tools & CRM mindset excellence mindset • Marketing & Sales investment • Ownership at every • Full p
Slide 36: Commercial Engine Gaining Traction
Commercial Engine Gaining Traction Customer penetration, pipeline expansion, and leading indicators of sustainable growth Sales Revenues Customers +53% Top 10 89 Growth in Total CDMOs Trials CDMOs +8% Sales performance Mol Tools Bioprocess -5% +23% +150% Increase in opportunity number +300% Increase
Slide 37: Value Beyond the Product
Design-In Commercialise Lock in Value Beyond the Product Qualified supplier status Validate at Scale Embedded in filings and Confirmed in pilot & SOPs De-Risk the Choice manufacturing Ongoing support & lifecycle Prove Documentation depth & Protects yield and cycle time management Revenue Performance
Slide 38: Embedded in a High-Growth Cancer Screening Platform
Embedded in a High-Growth Cancer Screening Platform Multi-year diagnostic partnership approaching regulatory decision and revenue ramp Company Track Record Legacy Past and future revenue - pending successful launch 20 Well-funded with history of moving fast History of collaboration. 18 to help preve
Slide 39: The True Value to Viral Vector Manufacturers
The True Value to Viral Vector Manufacturers We address the largest overlooked cost driver of viral vector manufacturing Customer Challenge Our Differentiation Operational Impact Economical Impact Up to 50% yield loss downstream SAN HQ and M-SAN HQ ~2× effective manufacturing capacity designed for c
Slide 40: A New Diagnostic Frontier
A New Diagnostic Frontier Unlocking the value of metagenomic diagnostics 2015 University of East Anglia, UK 645 Citations since 2019 Blood 2024 4 Years University of Inland, Norway 7 NHS sites using for Support ICU patients today 2019 University of East Anglia, UK Urine UK Government funded programs
Slide 41: Case Studies
Case Studies Stockholm, 06.03.2026
Slide 42: Enhanced purification of Lentiviral vectors using M-SAN nuclease
Enhanced purification of Lentiviral vectors using M-SAN nuclease Lee Davies
Slide 43: Legal disclaimer
Legal disclaimer This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reason
Slide 44: An unmatched 30-year track record in viral vector manufacturing
An unmatched 30-year track record in viral vector manufacturing Innovation-led CDMO specializing in viral vectors DEVELOPMENT 1995 OXB spins-out from Oxford University COMPANY PRODUCT 2008 World’s first patient treated in vivo with OXB lentiviral vectors Deal signed with Novartis for LV manufacturin
Slide 45: OXB
OXB Quality and Innovation-Led CDMO focused on life saving cell and gene therapies Global network delivering multi-site development and manufacturing capabilities > 1000 successful GMP batches > 30 successful IND submissions > 100 successful regulatory audits More than 40 countries with approved pro
Slide 46: Companies we are supporting
Companies we are supporting Manufacturing AAV, lentiviral, and adenoviral vectors Vector by Indication Vector pipeline Autoimmune Others Lentivirus Other 13% CF 3% 17% 37% 13% CNS 51% 32% AAV 9% 25% Oncology Ophthalmology Data as of April 2025 Our clients include: 46 Client logos represent a selecti
Slide 47: Lentiviral vectors for gene and cell therapy
Lentiviral vectors for gene and cell therapy • Typically based on HIV-1 virus • Modified to deliver therapeutic genes to patients • Wide range of disease targets • ~ 300 trials ongoing worldwide • 6 products approved by FDA for commercial supply • Dominant vector choice for CAR-T cancer therapies •
Slide 48: Lentiviral vectors
Lentiviral vectors Nucleocapsid Envelope Process limitations • Challenging vectors to manufacture • Easily inactivated by processing conditions RNA • Temperature Capsid • Time • pH (6.9 – 7.5) • Salt concentration (130 mM – 150 mM) Reverse • Manufacturing process defined by vector stability Transcri
Slide 49: OXB lentiviral vector manufacturing process
OXB lentiviral vector manufacturing process 49 OXB Confidential
Slide 50: Lentiviral vector quality challenge
Lentiviral vector quality challenge Residual impurities Bald particles Process Host Cell Plasmid Residuals Protein DNA Host Cell Protein DNA Empty particles aggregates Functional vector • Lentivirus vector quality is essential to assure patient safety • DNA from cells and plasmids used for productio
Slide 51: Nucleases for Host DNA Removal
Nucleases for Host DNA Removal Size LVV Harvest markers Harvest + nuclease • DNA and lentiviral vectors share physical characteristics • Strong negative charge • Large biomolecules DNA fragment size • Extremely difficult to separate using physical processing methods • Purification dependent on degra
Slide 52: Challenges with current nucleases
Challenges with current nucleases Enzyme operating conditions Optimum [NaCl] for nuclease activity Optimum pH for nuclease activity Physiological salt Lentivirus 7.2 ± 0.3 130 - 150 mM Nuclease B 8.0 - 9.2 Nuclease B 0 - 20 Nuclease D 8.0 - 9.0 Nuclease D 0 - 20 SAN 8.0 - 8.9 SAN 400 - 700 6.5 6.9 7
Slide 53: Degradation of DNA in OXB process
Degradation of DNA in OXB process Lentiviral vector purification Bioreactor Harvest & Purification & Fill/Finish & Clarification Formulation production collection concentration packaging Final drug product Nuc B Nuc B 53
Slide 54: M-SAN endonuclease
M-SAN endonuclease
Slide 55: ArcticZymes M-SAN endonuclease
ArcticZymes M-SAN endonuclease Optimum pH for nuclease activity Lentivirus 7.2 ± 0.3 Nuclease B 8.0 - 9.2 • Alternative nuclease for bioprocessing applications M-SAN 7.2 - 8.7 • More aligned with lentiviral vector requirements • Potential to improve offerings to clients SAN 8.0 - 8.9 6.5 6.9 7.5 8.5
Slide 56: M-SAN – Evaluation at OXB
M-SAN – Evaluation at OXB 5 L Production Bioreactors Bioreactor Harvest & Purification & Fill/Finish & Clarification Formulation production collection concentration packaging Final drug product M-SAN M-SAN 56
Slide 57: Enhanced DNA removal with M-SAN
Enhanced DNA removal with M-SAN 5 L Production Bioreactors Total DNA Plasmid DNA Small cellular DNA Large cellular DNA Residual nuclease 1.0 1.0 1.0 1.0 1.0 0.5 0.5 0.5 0.5 0.5 0.0 0.0 0.0 0.0 0.0 B N B N B B B N N N e A e A as as se A se A se A -S -S -S -S -S le le a a a M M le le le M M M uc uc uc
Slide 58: M-SAN – Single nuclease step
M-SAN – Single nuclease step 5 L Production Bioreactors Bioreactor Harvest & Purification & Fill/Finish & Clarification Formulation production collection concentration packaging Final drug product Impact Reduced process material costs M-SAN Reduced overall manufacturing time by 3 hrs Simplified manu
Slide 59: M-SAN conclusions
M-SAN conclusions Reduced manufacturing costs, complexity and processing time New process supports higher product yields with improved quality profile OXB can maintain profit margins and market share whilst delivering improved process More doses available to support increased patient numbers 59
Slide 60: Let's deliver life-changing therapies together
Let’s deliver life-changing therapies together A global quality and innovation-led CDMO in cell and gene therapy OXB.com
Slide 61: Clinical Metagenomics for Rapid Detection of Infections and Antimicrobial Resistance
Clinical Metagenomics for Rapid Detection of Infections and Antimicrobial Resistance Prof. Rafi Ahmad, PhD ArcticZymes Capital Market Days
Slide 62: Some Basic Terminologies
Some Basic Terminologies Genomics Isolated DNA Analysis h Single ORGamism Studying the DNA of a single, isolated organism Metagenomics Mixed Microbial Analysis Multiple Organisms Studying DNA from diverse microbial communities
Slide 63: Funded by UTI-Diag
Funded by UTI-Diag The Research Council of Norway “¥ NIPH ey TUKGM« Norwegian Institute of Public Health % UNIVERSITATSKLINIKUM % $ ” UNN * GIESSEN UND MARBURG lis World Health European Association of Urology Organization bt University of INN Inland Norway
Slide 64: Burden of Urinary Tract Infections (UTIs)
Burden of Urinary Tract Infections (UTIs)
Slide 65: Acknowledging the people behind the science
Acknowledging the people behind the science…..
Slide 66: Two-phase clinical study
Two-phase clinical study Under Review:
Slide 67: Why is it Complicated to Diagnose UTIs
Why is it Complicated to | Abundant 2 amounts of human DN . Thick biofilms with diverse pathogens overshadow small quantities j 6 ‘ . hamper efficient bacterial DNA & of bacterial DNA Ze Urine Sample as of Conislicated BSS UTI Patients d Thick biofilms with diverse eo hamper efficient bacterial DNA
Slide 68: Extracting Bacterial DNA from Clinical Blood & Urine
Extracting Bacterial DNA from Clinical Blood & Urine is Like Finding a Needle in a Haystack Clinical Samples , Comparison (4 Extracting bacterial DNA is like = isolating a tiny, hidden target amidst = vast human and host material!
Slide 69: Methodology - Part I: Host depletion
Methodology - Part I: Host depletion
Slide 70: Methodology - Part 2: DNA extraction
Methodology - Part 2: DNA extraction
Slide 71: Overview of the tested methods
Overview of the 11 tested methods
Slide 72: ~1000-fold depletion of host DNA using the optimized method
~1000-fold depletion of host DNA using the optimized method
Slide 73: Pathogen ID: 99% accuracy v Clinical Routine
Pathogen ID: 99% accuracy v Clinical Routine
Slide 74: AST: 92% accuracy v Clinical Routine
AST : 92% accuracy v Clinical Routine
Slide 75: 4 Hours Turn-around-time for UTI Diagnosis
4 Hours Turn-around-time for UTI Diagnosis
Slide 76: Cost-effective method: 36$/samples
Cost-effective method: 36$/samples
Slide 77: Conclusions & Future Plans
Conclusions & Future Plans • Culture-independent direct diagnosis is possible • Save millions of lives, reduce health care burden • Fewer hospital stays, fewer loss of workdays • Prudent use of antibiotics. Save on 1.6 billion doses/year • Flow cytometry and DNA could be relevant factors for culture
Slide 78: Diagnosis of Infection & AMR: Blood samples (Sepsis)
Diagnosis of Infection & AMR: Blood samples (Sepsis)
Slide 79: Sepsis: Time is Critical
Sepsis: Time is Critical 79 Source: National Sepsis Alliance Fact Sheet
Slide 80: White blood cells effectively target and eliminate bacteria in the blood
White blood cells effectively target and eliminate bacteria in the blood hole Blood Cells © i eicoawte Host DNA contamination “can interfere with PCR and . @) cause bias against bacterial / DNA Woast Excess Vast Blood Cells s PCR Amplification of Host Cells > Difficulties & Bias Blood samples contai
Slide 81: Blood cultures - Clinical study design
Blood cultures - Clinical study design 152 patient samples • 116 culture positive • 36 culture negative
Slide 82: Blood cultures - Clinical study initial results
Blood cultures - Clinical study initial results
Slide 83: Ny norskutviklet hurtigtest kan redde liv
e Vil redusere overforbruk av Ly I< antibiotika og gi legene raskere prevesvar Ny norskutviklet hurtigtest kan redde liv Raskere tester av bakteriepraver kan bety mye i kampen mot resistente bakterier. Na har Universitetet i Innlandet kommet langt ien losning. Jawad Ali gir nettopp Rafi Ahmad zeren
Slide 84: Some Market Forecasts
Some Market Forecasts Global Metagenomics Market Share, by Application, 2023 (%) <a @ Environmental © Clinical Diagnostics @ Food & Nutrition Drug Discovery @ Others GRAND VIEW RESEARCH $2.0B Global Market Size, 2023 Biotechnology Source: www.grandviewresearch.com
Slide 85: Key Investment Takeaways
Key Investment Takeaways • 15–20% CAGR expected • Infectious disease diagnostics is the primary driver • Falling sequencing costs enable hospital adoption • Bioinformatics + regulatory validation remain bottlenecks
Slide 86: University of Inland Norway
INN University of Inland Norway
Slide 87: Financial Profile & Capital Allocation
Financial Profile & Capital Allocation Stockholm, 06.03.2026
Slide 88: Strong platform for value creation
Strong platform for value creation Company and market evolution demands clear strategic direction Robust balance sheet Scalable business Stable OPEX and liquidity model with momentum allowing margin position picking up expansion Revenue (NOK million) Operational expenses (NOK million) 265 NOK millio
Slide 89: Scalable Platform with Largely Fixed Cost Base
Scalable Platform with Largely Fixed Cost Base Revenue growth expected to outpace cost growth Expense development 2020 - 2025 Personnel remains the core 120 000 cost driver • 2/3 of total operating expenses 100 000 • Aligned with revenue generation Other opex capacity 80 000 Licensing, patenting and
Slide 90: Operating Leverage - Structural Earnings Expansion
Operating Leverage - Structural Earnings Expansion Scaling the enzyme platform with largely fixed cost base* Revenue 120 MNOK 150 MNOK 200 MNOK Revenue growth - 25% 67% Gross margin 95-98% 95-98% 95-98% EBITDA Margin 10-15% 20-27% 30-35% EBITDA 12 -18 MNOK 30 - 40 MNOK 60 - 70 MNOK *Illustrative bus
Slide 91: Capital Allocation for Sustainable Value Creation
Capital Allocation for Sustainable Value Creation Organic growth first. Selective value accretive expansion options Disciplined capital allocation priorities enabling robust growth and sustainable value creation 1 Organic growth Financial strength 2 Allocation priorities Inorganic opportunities Cash
Slide 92: Ambition, Execution Priorities & Investment case
Ambition, Execution Priorities & Investment case
Slide 93: Driving Scalable Profitable Growth
Driving Scalable Profitable Growth Financial ambition. Disciplined focused execution. OUR AMBITION OUR EXECUTION Core priorities (2026-2028): Sustainable double-digit growth, targeting outperformance of served markets: Scale a high-performance commercial engine Innovation through R&D and partner
Slide 94: Building a Scalable, Differentiated Enzyme Platform
Building a Scalable, Differentiated Enzyme Platform Diversified exposure. Validated technology. Embedded revenue. Compounding model. High Gross margin Structural Diversification Across 1 High-Growth End Markets solutions Proven Differentiation in Customer- 2 Critical Applications Recurring enzyme Sc
Slide 95: Thank you
ArcticZymes Technologies *
Slide 96: Glossary
Glossary Appendix 1 Dx – Abbreviation for Diagnostics DNA – The molecule used to store genetic information. It is comprised of 4 different molecules, the order of which defines the code RNA – The molecule which amongst other things, transfers the genetic code from DNA to proteins. RNA is very simila
Slide 97: References and Data Sources
References and Data Sources Appendix 2 Reference Type Strategy Research And Markets (2025) Market report RNA Zion (2025) Market report RNA GMI Insights (2025) Market report RNA Towards Healthcare (2025) Market report RNA Nova One Advisor (2025) Market report RNA Strategic Market Research (2025) Mark
Slide 98: References and Data Sources
References and Data Sources Appendix 2 Reference Type Strategy 22nd Annual Report Survey Biomanufacturing Bioplan Market report Viral Vector BCC - Global Markets for Media, Sera and Reagents in Biotechnology Market report Viral Vector Viral Vector and Plasmid DNA 2024 Market report Viral Vector Cell
Slide 99: References and Data Sources
References and Data Sources Appendix 2 Reference Type Strategy Metagenomics KOL Interviews 25 x 3 KOL Molecular tools Internal customer feedback 24-15 KOL Molecular tools 99